E. David Crawford, MD, shares insight on incorporating ADT, specifically degarelix, into the prostate cancer landscape and why it remains to be a standard go-to approach for patients.
Susan F. Slovin, MD, PhD, discusses the current state of immunotherapy in prostate cancer.
Scott Tagawa, MD, discusses the latest findings with sacituzumab govitecan in patients with metastatic urothelial cancer.
As the number of tumor types with approved PD-1/PD-L1 pathway inhibitors continues to expand, bladder cancer has become a robust area of development.
Arlene O. Siefker-Radtke, MD, discusses the exciting advances in the bladder cancer field, why researchers should move past PD-L1 as a biomarker, and what combinations can be expected to move through the pipeline next.
Paul G. Corn, MD, PhD, discusses recent advances in prostate cancer and the potential for immunotherapy and PARP inhibitors in the field.
Seungtaek L. Choi, MD, discussed the latest developments with radiation therapy in prostate cancer.
Leonard Gomella, MD, discusses the current state and critical next steps for optimizing genetic testing in prostate cancer.
Brian F. Chapin, MD, discusses the importance of active surveillance in patients with prostate cancer at a low risk of developing metastases and the benefits of surgery and radiation as active treatment methods for patients with locally advanced disease.
Developing and validating a predictive model for patient-reported health-related quality of life remains an elusive target, and one that has great potential to further improve satisfaction with outcome following prostate cancer treatment in a great number of prostate cancer survivors.